Troels Holz Borch

15PUBLICATIONS
54CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyGene and molecular therapyMechanobiologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Aug 20, 2026
Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy.

|Jun 25, 2026
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.

|May 18, 2026
Phenotypic and Functional Characteristics of CD8+ T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma.

|Oct 19, 2025
Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF-mutant metastatic melanoma: a real-world propensity score-matched survival analysis.

Yago Garitaonaindia, Shawez Khan, Rasmus Friis

|Feb 06, 2025
Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes.

Troels Holz Borch, Rikke Andersen, Helle Westergren Hendel

|Mar 26, 2024
Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial.

Renske M T Ten Ham, Maartje W Rohaan, Inge Jedema

Pageof 3

Frequent Collaborators

10 joint publications

Marco Donia

5 joint publications

Inge Marie Svane

4 joint publications

Morten Nielsen

3 joint publications

John Haanen